On February 8, Neuromins applied for its fourth listing on the Main Board of the Hong Kong Stock Exchange. Its products can be broadly classified into five categories, DHA, probiotics, vitamins, multivitamins, and calcium algae. In 2020, Neuromins’ annual revenue was RMB 235 million yuan (USD $36.5 million), and net profit was RMB 166 million yuan (USD $25.7 million). The company believes that its continued growth of revenue and net profit is mainly due to the increasing health consciousness and income of Chinese consumers and the expansion of the company’s sales and distribution network. In addition, the company’s business is exposed to risks including the impact of the new coronavirus, the concentration of suppliers, inability to fully control the quality of products, and dependence on regional distributors. (Source: sohu.com)

Comments are closed.